Alexis Rompré-Brodeur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alexis Rompré-Brodeur has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
Fadi Brimo
Department of Pathology, McGill University Health Center, Montreal, Quebec, Canada
4 shared publicationsMaurice Anidjar
Division of Urology, Department of Surgery, McGill University Health Centre, McGill University, Montreal, Canada
4 shared publicationsDeepika Sirohi
Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah (D.S.)
3 shared publicationsF. Bladou
3 shared publicationsFahmin Basher
Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina (F.B.)
3 shared publicationsG. Marcq
3 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Wiley in BJU International
Somatic‐to‐autonomic ilioinguinal nerve grafting for post‐radical prostatectomy erectile dysfunction
Objectives: To evaluate the safety and feasibility of a novel somatic‐to‐autonomic nerve grafting procedure for erectile function restoration in men with persistent erectile dysfunction (ED) following radical prostatectomy (RP). Patients and Methods: A total of 10 patients with normal pre‐RP erectile function defined by a five‐item International Index of Erectile Function (IIEF‐5) score ≥17, and persistent ED (IIEF‐5 score ≤7) for >18 months after RP were enrolled in this pilot trial. A novel bilateral end‐to‐side neurorrhaphy was performed between the dorsal penile nerves and the corpora cavernosa using an ilioinguinal nerve autograft. Baseline assessments included the IIEF‐5 and Clinical Evolution of Erectile Function (CEEF) questionnaires for erectile function and McGill University's validated short‐form pain questionnaire. Postoperative evaluations were performed at 1, 3, 6, and 12 months. Data collection includes demographics, perioperative outcomes, and both primary (safety/feasibility) and secondary (erectile function) endpoints. Results: The median (interquartile range [IQR]) patient age was 63.5 (57.5–67.3) years. Three patients had undergone non‐nerve‐sparing, four had unilateral nerve‐sparing, and three had bilateral nerve‐sparing RP. The median (IQR) IIEF‐5 score before RP was 25 (25–25), dropping to 5 (5–5) after RP. The median (IQR) time from RP to nerve grafting was 34.7 (22.5–39.2) months with a median (IQR) operative time of 76.5 (70–82.8) min. Postoperative incisional pain was minimal. Six patients reported mild ipsilateral scrotal numbness. One patient developed a Clavien–Dindo Grade II wound infection, while two patients had Grade I haematomas. At the 12‐month follow‐up, all patients experienced a significant improvement in subjective erectile function from a median score of 0/10 to 7/10 ( P = 0.004). The median (IQR) IIEF‐5 score at the 12‐month follow‐up was 10 (5–14) achieving statistical significance ( P = 0.031), and five patients had regained erections sufficient for penetrative intercourse. Conclusion: This study suggests that bilateral end‐to‐side neurorrhaphy using an ilioinguinal nerve autograft is feasible and safe. The 1‐year erectile function recovery data is promising, showing meaningful improvements from baseline. This technique may offer a novel therapeutic avenue for post‐RP ED and warrants further investigation in larger trials.
- 17 November 2026
- Published by Wiley in BJU International
Open AccessSomatic‐to‐autonomic ilioinguinal nerve grafting for post‐radical prostatectomy erectile dysfunction
Objectives: To evaluate the safety and feasibility of a novel somatic‐to‐autonomic nerve grafting procedure for erectile function restoration in men with persistent erectile dysfunction (ED) following radical prostatectomy (RP). Patients and Methods: A total of 10 patients with normal pre‐RP erectile function defined by a five‐item International Index of Erectile Function (IIEF‐5) score ≥17, and persistent ED (IIEF‐5 score ≤7) for >18 months after RP were enrolled in this pilot trial. A novel bilateral end‐to‐side neurorrhaphy was performed between the dorsal penile nerves and the corpora cavernosa using an ilioinguinal nerve autograft. Baseline assessments included the IIEF‐5 and Clinical Evolution of Erectile Function (CEEF) questionnaires for erectile function and McGill University's validated short‐form pain questionnaire. Postoperative evaluations were performed at 1, 3, 6, and 12 months. Data collection includes demographics, perioperative outcomes, and both primary (safety/feasibility) and secondary (erectile function) endpoints. Results: The median (interquartile range [IQR]) patient age was 63.5 (57.5–67.3) years. Three patients had undergone non‐nerve‐sparing, four had unilateral nerve‐sparing, and three had bilateral nerve‐sparing RP. The median (IQR) IIEF‐5 score before RP was 25 (25–25), dropping to 5 (5–5) after RP. The median (IQR) time from RP to nerve grafting was 34.7 (22.5–39.2) months with a median (IQR) operative time of 76.5 (70–82.8) min. Postoperative incisional pain was minimal. Six patients reported mild ipsilateral scrotal numbness. One patient developed a Clavien–Dindo Grade II wound infection, while two patients had Grade I haematomas. At the 12‐month follow‐up, all patients experienced a significant improvement in subjective erectile function from a median score of 0/10 to 7/10 ( P = 0.004). The median (IQR) IIEF‐5 score at the 12‐month follow‐up was 10 (5–14) achieving statistical significance ( P = 0.031), and five patients had regained erections sufficient for penetrative intercourse. Conclusion: This study suggests that bilateral end‐to‐side neurorrhaphy using an ilioinguinal nerve autograft is feasible and safe. The 1‐year erectile function recovery data is promising, showing meaningful improvements from baseline. This technique may offer a novel therapeutic avenue for post‐RP ED and warrants further investigation in larger trials.
- Open Access
- 8 April 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (2) , 21
Dedifferentiated Liposarcoma Mimicking a Bosniak IV Cyst: A Rare Case of Radiographic Mimicry
Cystic renal lesions are frequently identified incidentally on imaging and range from benign cysts to malignant tumors
- 8 April 2026
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 7 (2) , 21
Open AccessDedifferentiated Liposarcoma Mimicking a Bosniak IV Cyst: A Rare Case of Radiographic Mimicry
Cystic renal lesions are frequently identified incidentally on imaging and range from benign cysts to malignant tumors
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (10)
Renal Cancer in Hereditary Leiomyomatosis and Renal Cell Cancer: A Scoping Review of Epidemiology, Clinical Features, Management, and Outcomes
Purpose: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare autosomal dominant syndrome caused by germline pathogenic variants in the fumarate hydratase ( FH ) gene. Affected individuals face up to a 15% to 20% lifetime risk of developing aggressive renal cell carcinoma (RCC). Despite well-defined syndromic features—cutaneous and uterine leiomyomas (ULs)—diagnosis is often delayed, and optimal management strategies remain poorly defined. This review aims to synthesize current evidence on the epidemiology, clinical features, diagnostic pathways, treatment strategies, and outcomes of HLRCC-associated RCC and to identify knowledge gaps and inform clinical and research priorities. Materials and Methods: We conducted a scoping review in accordance with PRISMA-ScR and the Arksey and O'Malley framework. Six databases (MEDLINE, Embase, Scopus, Web of Science, CENTRAL, ClinicalTrials.gov) were searched from inception through July 30, 2024. Studies with original data on RCC in confirmed or suspected HLRCC were included. Data were extracted and synthesized from individual patient data (IPD) and observational cohorts and presented using descriptive statistics and narrative synthesis. Results: A total of 149 studies were included, comprising 382 IPD from case reports/series and 16 observational cohorts. RCC occurred at a mean age of 39.4 years and presented symptomatically in > 85% of cases. Despite frequent syndromic features (ULs: 80.9%, cutaneous leiomyomas: 47.5%), < 15% of patients underwent FH testing before cancer diagnosis. Tumors were large (mean 7.6 cm), often metastatic (stage IV in 52.3% of IPD), and showed high rates of FH loss (95.9%) and 2SC positivity (94%-100%). Nephrectomy was the most common treatment; systemic therapy was infrequently reported. Limited observation data suggest potential benefit of tyrosine kinase inhibitors, vascular endothelial growth factor inhibitors, and immune-targeted therapies. Early-stage disease was associated with improved survival (>80 months). Median survival in metastatic cases ranged from 15 to 35 months. Conclusions: HLRCC-associated RCC remains underdiagnosed and frequently presents at advanced stages. Earlier genetic testing, greater syndromic recognition, and multidisciplinary surveillance are needed to enable timely detection. Evidence for systemic therapy is limited, and prospective trials are urgently needed to define optimal management. Coordinated research efforts and biomarker-driven diagnostic strategies will be essential to improving outcomes for this aggressive hereditary kidney cancer subtype.
- 1 October 2025
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 3 (10)
Open AccessRenal Cancer in Hereditary Leiomyomatosis and Renal Cell Cancer: A Scoping Review of Epidemiology, Clinical Features, Management, and Outcomes
Purpose: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare autosomal dominant syndrome caused by germline pathogenic variants in the fumarate hydratase ( FH ) gene. Affected individuals face up to a 15% to 20% lifetime risk of developing aggressive renal cell carcinoma (RCC). Despite well-defined syndromic features—cutaneous and uterine leiomyomas (ULs)—diagnosis is often delayed, and optimal management strategies remain poorly defined. This review aims to synthesize current evidence on the epidemiology, clinical features, diagnostic pathways, treatment strategies, and outcomes of HLRCC-associated RCC and to identify knowledge gaps and inform clinical and research priorities. Materials and Methods: We conducted a scoping review in accordance with PRISMA-ScR and the Arksey and O'Malley framework. Six databases (MEDLINE, Embase, Scopus, Web of Science, CENTRAL, ClinicalTrials.gov) were searched from inception through July 30, 2024. Studies with original data on RCC in confirmed or suspected HLRCC were included. Data were extracted and synthesized from individual patient data (IPD) and observational cohorts and presented using descriptive statistics and narrative synthesis. Results: A total of 149 studies were included, comprising 382 IPD from case reports/series and 16 observational cohorts. RCC occurred at a mean age of 39.4 years and presented symptomatically in > 85% of cases. Despite frequent syndromic features (ULs: 80.9%, cutaneous leiomyomas: 47.5%), < 15% of patients underwent FH testing before cancer diagnosis. Tumors were large (mean 7.6 cm), often metastatic (stage IV in 52.3% of IPD), and showed high rates of FH loss (95.9%) and 2SC positivity (94%-100%). Nephrectomy was the most common treatment; systemic therapy was infrequently reported. Limited observation data suggest potential benefit of tyrosine kinase inhibitors, vascular endothelial growth factor inhibitors, and immune-targeted therapies. Early-stage disease was associated with improved survival (>80 months). Median survival in metastatic cases ranged from 15 to 35 months. Conclusions: HLRCC-associated RCC remains underdiagnosed and frequently presents at advanced stages. Earlier genetic testing, greater syndromic recognition, and multidisciplinary surveillance are needed to enable timely detection. Evidence for systemic therapy is limited, and prospective trials are urgently needed to define optimal management. Coordinated research efforts and biomarker-driven diagnostic strategies will be essential to improving outcomes for this aggressive hereditary kidney cancer subtype.
- Open Access
- 18 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5839
Refined Procedure to Purify and Sequence Circulating Cell-Free DNA in Prostate Cancer
Cell-free DNA (cfDNA), a fragmented DNA circulating in blood, is a promising biomarker for cancer diagnosis and monitoring. Standardization of cfDNA isolation to enhance the sensitivity of molecular analyses in prostate cancer (PCa) is required. Towards this goal, we optimized existing methods to obtain a high quantity and quality of cfDNA from low volumes of plasma. The protocol was applied to samples from healthy males and three patient categories: radical prostatectomy (RP), disease-free (>6 years post-RP), and metastatic castration-resistant PCa (mCRPC). The yield was significantly higher in mCRPC cases, and the size of fragments was shorter. We compared for the first time library preparation using two cfDNA inputs and low vs. high sequencing depth. Clonal events were observed irrespective of input and depth, but lower input showed more subclonal events. The clinical application of the refined protocols to cfDNA samples from an mCRPC patient showed no tumor fraction before RP, while it increased to 25% at the advanced stage. Among chromosomal changes and mutations, the androgen receptor gene amplification was detected. Altogether, this comprehensive study on improved cfDNA procedures is highly promising to enhance the quality of liquid biopsy-based research for discoveries and much-needed clinical applications.
- 18 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5839
Open AccessRefined Procedure to Purify and Sequence Circulating Cell-Free DNA in Prostate Cancer
Cell-free DNA (cfDNA), a fragmented DNA circulating in blood, is a promising biomarker for cancer diagnosis and monitoring. Standardization of cfDNA isolation to enhance the sensitivity of molecular analyses in prostate cancer (PCa) is required. Towards this goal, we optimized existing methods to obtain a high quantity and quality of cfDNA from low volumes of plasma. The protocol was applied to samples from healthy males and three patient categories: radical prostatectomy (RP), disease-free (>6 years post-RP), and metastatic castration-resistant PCa (mCRPC). The yield was significantly higher in mCRPC cases, and the size of fragments was shorter. We compared for the first time library preparation using two cfDNA inputs and low vs. high sequencing depth. Clonal events were observed irrespective of input and depth, but lower input showed more subclonal events. The clinical application of the refined protocols to cfDNA samples from an mCRPC patient showed no tumor fraction before RP, while it increased to 25% at the advanced stage. Among chromosomal changes and mutations, the androgen receptor gene amplification was detected. Altogether, this comprehensive study on improved cfDNA procedures is highly promising to enhance the quality of liquid biopsy-based research for discoveries and much-needed clinical applications.
- 1 February 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (2) , 218-228
Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer
Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations. To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions on treatment choice among patients with localized PCa considering first-line treatment. MEDLINE, EMBASE, and Web of Science published from January 2010 to August 2024. Two investigators independently identified studies on risk classification and treatment choice after GC testing for patients with localized PCa considering first-line treatment. Relevant data extracted by 1 researcher and overread by a second. Risk of bias (ROB) was assessed in duplicate. Ten studies reported risk reclassification after GC testing. In low ROB observational studies, very low- or low-risk patients with PCa were more likely to have their risk levels classified as the same or lower (GPS, 100% to 88.1%; Decipher, 87.2% to 82.9%; Prolaris, 76.9%). However, 1 randomized trial found that GC testing with GPS reclassified 34.5% of very low-risk and 29.4% of low-risk patients to a higher risk category. Twelve observational studies indicated that treatment decisions after GC testing either remained unchanged or slightly favored active surveillance. In contrast, analyses from a single randomized trial found fewer choices for active surveillance after GPS testing. Heterogeneity in screening patterns, risk-determination cutoffs, pathology, and clinical practices. Studies on treatment choice were moderate to high ROB. Although GC tests do not consistently influence risk classification or treatment decisions, the differences observed between observational and randomized studies highlight a need for well-designed trials to explore the role of GC tests in patients with newly diagnosed PCa considering first-line treatment. U.S. Department of Veterans Affairs. (PROSPERO: CRD42022347950).
- 1 February 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (2) , 218-228
Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer
Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations. To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions on treatment choice among patients with localized PCa considering first-line treatment. MEDLINE, EMBASE, and Web of Science published from January 2010 to August 2024. Two investigators independently identified studies on risk classification and treatment choice after GC testing for patients with localized PCa considering first-line treatment. Relevant data extracted by 1 researcher and overread by a second. Risk of bias (ROB) was assessed in duplicate. Ten studies reported risk reclassification after GC testing. In low ROB observational studies, very low- or low-risk patients with PCa were more likely to have their risk levels classified as the same or lower (GPS, 100% to 88.1%; Decipher, 87.2% to 82.9%; Prolaris, 76.9%). However, 1 randomized trial found that GC testing with GPS reclassified 34.5% of very low-risk and 29.4% of low-risk patients to a higher risk category. Twelve observational studies indicated that treatment decisions after GC testing either remained unchanged or slightly favored active surveillance. In contrast, analyses from a single randomized trial found fewer choices for active surveillance after GPS testing. Heterogeneity in screening patterns, risk-determination cutoffs, pathology, and clinical practices. Studies on treatment choice were moderate to high ROB. Although GC tests do not consistently influence risk classification or treatment decisions, the differences observed between observational and randomized studies highlight a need for well-designed trials to explore the role of GC tests in patients with newly diagnosed PCa considering first-line treatment. U.S. Department of Veterans Affairs. (PROSPERO: CRD42022347950).
- 10 January 2024
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 28 (1) , 103-111
Genomic classifiers and prognosis of localized prostate cancer: a systematic review
Background Refinement of the risk classification for localized prostate cancer is warranted to aid in clinical decision making. A systematic analysis was undertaken to evaluate the prognostic ability of three genomic classifiers, Decipher, GPS, and Prolaris, for biochemical recurrence, development of metastases and prostate cancer-specific mortality in patients with localized prostate cancer. Methods Data sources: MEDLINE, Embase, and Web of Science were queried for reports published from January 2010 to April 2022. Study selection: prospective or retrospective studies reporting prognosis for patients with localized prostate cancer. Data extraction: relevant data were extracted into a customized database by one researcher with a second overreading. Risk of bias was assessed using a validated tool for prognostic studies, Quality in Prognosis Studies (QUIPS). Disagreements were resolved by consensus or by input from a third reviewer. We assessed the certainty of evidence by GRADE incorporating adaptation for prognostic studies. Results Data synthesis: a total of 39 studies (37 retrospective) involving over 10,000 patients were identified. Twenty-two assessed Decipher, 5 GPS, and 14 Prolaris. Thirty-four studies included patients who underwent prostatectomy. Based on very low to low certainty of evidence, each of the three genomic classifiers modestly improved upon the prognostic ability for biochemical recurrence, development of metastases, and prostate cancer-specific mortality compared to standard clinical risk-classification schemes. Limitations: downgrading of confidence in the evidence stemmed largely from bias due to the retrospective nature of the studies, heterogeneity in treatment received, and era in which patients were treated (i.e., prior to the 2000s). Conclusions Genomic classifiers provide a small but consistent improvement upon the prognostic ability of clinical classification schemes, which may be helpful when treatment decisions are uncertain. However, evidence from current management-era data and of the predictive ability of these tests is needed.
- 10 January 2024
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 28 (1) , 103-111
Genomic classifiers and prognosis of localized prostate cancer: a systematic review
Background Refinement of the risk classification for localized prostate cancer is warranted to aid in clinical decision making. A systematic analysis was undertaken to evaluate the prognostic ability of three genomic classifiers, Decipher, GPS, and Prolaris, for biochemical recurrence, development of metastases and prostate cancer-specific mortality in patients with localized prostate cancer. Methods Data sources: MEDLINE, Embase, and Web of Science were queried for reports published from January 2010 to April 2022. Study selection: prospective or retrospective studies reporting prognosis for patients with localized prostate cancer. Data extraction: relevant data were extracted into a customized database by one researcher with a second overreading. Risk of bias was assessed using a validated tool for prognostic studies, Quality in Prognosis Studies (QUIPS). Disagreements were resolved by consensus or by input from a third reviewer. We assessed the certainty of evidence by GRADE incorporating adaptation for prognostic studies. Results Data synthesis: a total of 39 studies (37 retrospective) involving over 10,000 patients were identified. Twenty-two assessed Decipher, 5 GPS, and 14 Prolaris. Thirty-four studies included patients who underwent prostatectomy. Based on very low to low certainty of evidence, each of the three genomic classifiers modestly improved upon the prognostic ability for biochemical recurrence, development of metastases, and prostate cancer-specific mortality compared to standard clinical risk-classification schemes. Limitations: downgrading of confidence in the evidence stemmed largely from bias due to the retrospective nature of the studies, heterogeneity in treatment received, and era in which patients were treated (i.e., prior to the 2000s). Conclusions Genomic classifiers provide a small but consistent improvement upon the prognostic ability of clinical classification schemes, which may be helpful when treatment decisions are uncertain. However, evidence from current management-era data and of the predictive ability of these tests is needed.
- Open Access
- 6 September 2023
- Published by Springer Nature in Research Square
Genomic Classifiers and Prognosis of Localized Prostate Cancer: A Systematic Review
Background Refinement of the risk classification for localized prostate cancer is warranted to aid in clinical decision making. A systematic analysis was undertaken to evaluate the prognostic ability of three genomic classifiers, Decipher, GPS, and Prolaris, for biochemical recurrence, development of metastases and prostate cancer specific mortality in patients with localized prostate cancer. Methods Data Sources: MEDLINE, Embase, and Web of Science were queried for reports published January 2010 to April 2022. Study Selection: Prospective or retrospective studies reporting prognosis for patients with localized prostate cancer. Data Extraction: Relevant data were extracted into a customized database by 1 researcher with a second over reading. Risk of bias was assessed using a validated tool for prognostic studies, Quality in Prognosis Studies (QUIPS). Disagreements were resolved by consensus or by input from a third reviewer. We assessed certainty of evidence by GRADE incorporating adaptation for prognostic studies. Results Data Synthesis: A total of 39 studies (37 retrospective) involving over 10 000 patients were identified. Twenty-two assessed Decipher, 5 GPS, and 14 Prolaris. Thirty-four studies included patients who underwent prostatectomy. Based on very low to low certainty of evidence, each of three genomic classifiers modestly improved upon the prognostic ability for biochemical recurrence, development of metastases, and prostate cancer specific mortality compared to standard clinical risk classification schemes Limitations: Downgrading of confidence in the evidence stemmed largely from bias due to the retrospective nature of the studies, heterogeneity in treatment received, and era in which patients were treated (i.e., prior to 2000s). Conclusions: Genomic classifiers provide a small but consistent improvement upon the prognostic ability of clinical classification schemes which may be helpful when treatment decisions are uncertain. However, definitive evidence from current management-era data is needed.
- 6 September 2023
- Published by Springer Nature in Research Square
Open AccessGenomic Classifiers and Prognosis of Localized Prostate Cancer: A Systematic Review
Background Refinement of the risk classification for localized prostate cancer is warranted to aid in clinical decision making. A systematic analysis was undertaken to evaluate the prognostic ability of three genomic classifiers, Decipher, GPS, and Prolaris, for biochemical recurrence, development of metastases and prostate cancer specific mortality in patients with localized prostate cancer. Methods Data Sources: MEDLINE, Embase, and Web of Science were queried for reports published January 2010 to April 2022. Study Selection: Prospective or retrospective studies reporting prognosis for patients with localized prostate cancer. Data Extraction: Relevant data were extracted into a customized database by 1 researcher with a second over reading. Risk of bias was assessed using a validated tool for prognostic studies, Quality in Prognosis Studies (QUIPS). Disagreements were resolved by consensus or by input from a third reviewer. We assessed certainty of evidence by GRADE incorporating adaptation for prognostic studies. Results Data Synthesis: A total of 39 studies (37 retrospective) involving over 10 000 patients were identified. Twenty-two assessed Decipher, 5 GPS, and 14 Prolaris. Thirty-four studies included patients who underwent prostatectomy. Based on very low to low certainty of evidence, each of three genomic classifiers modestly improved upon the prognostic ability for biochemical recurrence, development of metastases, and prostate cancer specific mortality compared to standard clinical risk classification schemes Limitations: Downgrading of confidence in the evidence stemmed largely from bias due to the retrospective nature of the studies, heterogeneity in treatment received, and era in which patients were treated (i.e., prior to 2000s). Conclusions: Genomic classifiers provide a small but consistent improvement upon the prognostic ability of clinical classification schemes which may be helpful when treatment decisions are uncertain. However, definitive evidence from current management-era data is needed.
- 9 August 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (11) , 3267-3276
The diagnostic accuracy of micro-ultrasound for prostate cancer diagnosis: a review
Purpose Micro-UltraSound (microUS) is a new imaging modality capable of identifying and targeting suspicious areas, which might further increase the diagnostic yield of prostate biopsy (PBx). Aim of this review is to provide insights into the usefulness of microUS for the sub-stratification of prostate cancer (PCa), clinically significant PCa (i.e., any Gleason score ≥ 7 PCa; csPCa) along with non-organ-confined disease in patients undergoing PBx. Methods A PubMed literature search was performed using keywords: prostate cancer diagnosis, prostate cancer diagnosis surveillance, systematic biopsy, target biopsy, micro-ultrasound, and prostate risk identification using micro-ultrasound. Results MicroUS could significantly improve multiparametric magnetic resonance imaging (mpMRI) findings by adding valuable anatomical and pathological information provided by real-time examination. Furthermore, microUS target biopsy could replace systematic biopsy in clinical practice by reducing the detection of clinically insignificant (ciPCa) and increasing that of csPCa. Finally, microUS may be useful in predicting the presence of non-organ confined PCa before radical prostatectomy and it could also be an effective add-on tool for patient monitoring within the active surveillance program. Conclusion MicroUS may represent an attractive step forward for the management of csPCa as a complementary or alternative tool to mpMRI. Nevertheless, further longitudinal studies are warranted, and the strength of the evidence is still suboptimal to provide clear recommendations for daily clinical practice.
- 9 August 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (11) , 3267-3276
The diagnostic accuracy of micro-ultrasound for prostate cancer diagnosis: a review
Purpose Micro-UltraSound (microUS) is a new imaging modality capable of identifying and targeting suspicious areas, which might further increase the diagnostic yield of prostate biopsy (PBx). Aim of this review is to provide insights into the usefulness of microUS for the sub-stratification of prostate cancer (PCa), clinically significant PCa (i.e., any Gleason score ≥ 7 PCa; csPCa) along with non-organ-confined disease in patients undergoing PBx. Methods A PubMed literature search was performed using keywords: prostate cancer diagnosis, prostate cancer diagnosis surveillance, systematic biopsy, target biopsy, micro-ultrasound, and prostate risk identification using micro-ultrasound. Results MicroUS could significantly improve multiparametric magnetic resonance imaging (mpMRI) findings by adding valuable anatomical and pathological information provided by real-time examination. Furthermore, microUS target biopsy could replace systematic biopsy in clinical practice by reducing the detection of clinically insignificant (ciPCa) and increasing that of csPCa. Finally, microUS may be useful in predicting the presence of non-organ confined PCa before radical prostatectomy and it could also be an effective add-on tool for patient monitoring within the active surveillance program. Conclusion MicroUS may represent an attractive step forward for the management of csPCa as a complementary or alternative tool to mpMRI. Nevertheless, further longitudinal studies are warranted, and the strength of the evidence is still suboptimal to provide clear recommendations for daily clinical practice.
- Open Access
Prophylactic A-Blockers for Radiotherapy-Induced Lower Urinary Tract Symptoms in Men with Prostate Cancer: A Phase III Randomized Trial
Purpose: The present phase III randomized trial assessed the efficacy of prophylactic versus therapeutic α-blockers at improving RI-LUTSs in prostate cancer patients receiving external beam radiotherapy (EBRT). Methods: A total of 148 prostate cancer patients were randomized 1:1 to receive either prophylactic silodosin on day one of EBRT or the occurrence of RI-LUTSs. LUTSs were quantified using the international prostate symptom score (IPSS) at regular intervals during the study. The primary endpoint was the change in the IPSS from baseline to the last day of radiotherapy (RT). Secondary endpoints included changes in IPSS from baseline to 4 weeks and 12 weeks after the start of RT. Results: Patient demographics, baseline IPSS, and prescribed radiation doses were balanced between arms. On the last day of RT, the mean IPSS was 14.8 (SD 7.6) in the experimental arm and 15.7 (SD 8.5) in the control arm (p = 0.40). There were no significant differences in IPSSs between the study arms in the intention-to-treat (ITT) analysis at baseline, the last day of RT, and 4 and 12 weeks post-RT. Conclusion: Prophylactic α-blockers were not effective at significantly reducing RI-LUTSs in prostate cancer patients treated with EBRT. Treating patients with α-blockers at the onset of RI-LUTSs will avoid unnecessary drug exposure and toxicity.
Open AccessProphylactic A-Blockers for Radiotherapy-Induced Lower Urinary Tract Symptoms in Men with Prostate Cancer: A Phase III Randomized Trial
Purpose: The present phase III randomized trial assessed the efficacy of prophylactic versus therapeutic α-blockers at improving RI-LUTSs in prostate cancer patients receiving external beam radiotherapy (EBRT). Methods: A total of 148 prostate cancer patients were randomized 1:1 to receive either prophylactic silodosin on day one of EBRT or the occurrence of RI-LUTSs. LUTSs were quantified using the international prostate symptom score (IPSS) at regular intervals during the study. The primary endpoint was the change in the IPSS from baseline to the last day of radiotherapy (RT). Secondary endpoints included changes in IPSS from baseline to 4 weeks and 12 weeks after the start of RT. Results: Patient demographics, baseline IPSS, and prescribed radiation doses were balanced between arms. On the last day of RT, the mean IPSS was 14.8 (SD 7.6) in the experimental arm and 15.7 (SD 8.5) in the control arm (p = 0.40). There were no significant differences in IPSSs between the study arms in the intention-to-treat (ITT) analysis at baseline, the last day of RT, and 4 and 12 weeks post-RT. Conclusion: Prophylactic α-blockers were not effective at significantly reducing RI-LUTSs in prostate cancer patients treated with EBRT. Treating patients with α-blockers at the onset of RI-LUTSs will avoid unnecessary drug exposure and toxicity.
- Open Access
Neoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature
Background: There is an ongoing debate on the optimal sequencing of androgen deprivation therapy (ADT) and radiotherapy (RT) in patients with localized prostate cancer (PCa). Recent data favors concurrent ADT and RT over the neoadjuvant approach. Methods: We conducted a systematic review in PubMed, EMBASE, and Cochrane Databases assessing the combination and optimal sequencing of ADT and RT for Intermediate-Risk (IR) and High-Risk (HR) PCa. Findings: Twenty randomized control trials, one abstract, one individual patient data meta-analysis, and two retrospective studies were selected. HR PCa patients had improved survival outcomes with RT and ADT, particularly when a long-course Neoadjuvant-Concurrent-Adjuvant ADT was used. This benefit was seen in IR PCa when adding short-course ADT, although less consistently. The best available evidence indicates that concurrent over neoadjuvant sequencing is associated with better metastases-free survival at 15 years. Although most patients had IR PCa, HR participants may have been undertreated with short-course ADT and the absence of pelvic RT. Conversely, retrospective data suggests a survival benefit when using the neoadjuvant approach in HR PCa patients. Interpretation: The available literature supports concurrent ADT and RT initiation for IR PCa. Neoadjuvant-concurrent-adjuvant sequencing should remain the standard approach for HR PCa and is an option for IR PCa.
Open AccessNeoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature
Background: There is an ongoing debate on the optimal sequencing of androgen deprivation therapy (ADT) and radiotherapy (RT) in patients with localized prostate cancer (PCa). Recent data favors concurrent ADT and RT over the neoadjuvant approach. Methods: We conducted a systematic review in PubMed, EMBASE, and Cochrane Databases assessing the combination and optimal sequencing of ADT and RT for Intermediate-Risk (IR) and High-Risk (HR) PCa. Findings: Twenty randomized control trials, one abstract, one individual patient data meta-analysis, and two retrospective studies were selected. HR PCa patients had improved survival outcomes with RT and ADT, particularly when a long-course Neoadjuvant-Concurrent-Adjuvant ADT was used. This benefit was seen in IR PCa when adding short-course ADT, although less consistently. The best available evidence indicates that concurrent over neoadjuvant sequencing is associated with better metastases-free survival at 15 years. Although most patients had IR PCa, HR participants may have been undertreated with short-course ADT and the absence of pelvic RT. Conversely, retrospective data suggests a survival benefit when using the neoadjuvant approach in HR PCa patients. Interpretation: The available literature supports concurrent ADT and RT initiation for IR PCa. Neoadjuvant-concurrent-adjuvant sequencing should remain the standard approach for HR PCa and is an option for IR PCa.